Filing Analysis
Vivos Therapeutics announced its intention to file a registration statement for a proposed rights offering. This offering would distribute transferable subscription rights to shareholders, allowing them to purchase common stock at specific exercise prices.
🚩 Red Flags
- Potential significant dilution of existing shareholders if the offering is completed.
- The need for a potential amendment to the certificate of incorporation suggests the company may lack sufficient authorized shares to complete the offering.
- Rights offerings in micro-cap companies are often indicative of urgent capital needs or difficulty accessing traditional debt/equity markets.
📋 Key Facts
- Announcement date: June 11, 2026; Filing date: June 16, 2026.
- Proposed exercise price for initial rights: Greater of $1.25 per share or 20% above the market price on the day before the record date.
- Rights are expected to be exercisable for a period of nine months.
- Upon exercise, holders are expected to receive a subsequent nine-month trading right with an exercise price of the greater of $1.75 per share or 40% above the market price.
- The offering is subject to SEC effectiveness and may require an amendment to the certificate of incorporation and a shareholder vote to increase authorized shares.
Vivos Therapeutics entered into a Collaboration Agreement on June 10, 2026, with South Palm Cardiovascular Associates, LLC (SPCVA) to form a new management services organization called AIM Florida, LLC. The entity will provide non-clinical support services for sleep apnea diagnostic and treatment services, primarily in Palm Beach County, Florida.
📋 Key Facts
- Collaboration Agreement signed June 10, 2026.
- Formation of AIM Florida, LLC to provide administrative, operational, billing, and marketing services.
- Vivos Therapeutics expects to hold at least 80% membership interest; SPCVA expects up to 20%.
- Vivos Provider Network, LLC (a wholly owned subsidiary) is intended to be the initial manager.
- Investment by SPCVA will be made at fair market value.
- Distributions and allocations will be proportional to membership interest, regardless of referral volume.
Vivos Therapeutics received a Nasdaq delisting notice due to a minimum bid price deficiency and is currently non-compliant with stockholders' equity requirements. To address liquidity and debt, the company entered into a complex debt-for-equity exchange agreement with Streeterville Capital and a new $5M convertible note with an affiliate, V-Co Investors 4 LLC.
🚩 Red Flags
- Delisting notice for minimum bid price deficiency.
- Explicit admission of non-compliance with Nasdaq's $2.4M minimum stockholders' equity requirement.
- Related-party transaction: The V-Co 4 Note is provided by an affiliate of an existing private equity investor/advisor.
- High dependency on immediate capital raises (June 15, 2026 deadline) to trigger debt relief and regain Nasdaq compliance.
- Multiple critical 8-K items (1.01, 2.03, 3.01, 3.02, 7.01) in a single filing.
📋 Key Facts
- Received Nasdaq notice on June 5, 2026, for failing to maintain a minimum bid price of $1.00; compliance deadline is December 2, 2026.
- Company admits it is currently not in compliance with Nasdaq's $2.4 million minimum stockholders' equity requirement.
- Entered into an Exchange Agreement with Streeterville Capital to convert portions of an $8.225M note into Series A Preferred Stock and Common Stock, contingent on raising $2.6M (First Tranche) and $1.9M (Second Tranche) by June 15, 2026.
- Issued an unsecured convertible promissory note to V-Co Investors 4 LLC (an affiliate of existing investor New Seneca Partners) for up to $5,000,000, with $500,000 already funded as of May 7, 2026.
- The Streeterville exchange, if completed, would extend the note maturity to June 10, 2027, and reduce monthly principal redemptions from $550,000 to $225,000.
Vivos Therapeutics received a deficiency notice from Nasdaq on April 17, 2026, for failing to maintain the minimum stockholders' equity requirement of $2.5 million. The company reported a negative stockholders' equity of approximately $1.55 million as of December 31, 2025.
🚩 Red Flags
- Negative stockholders' equity of $1.55 million.
- Receipt of a formal Nasdaq delisting notice.
- Heavy reliance on dilutive equity financing to maintain listing requirements.
📋 Key Facts
- Nasdaq notice received on April 17, 2026, regarding Rule 5550(b)(1) non-compliance.
- Stockholders' equity was negative $1.55 million as of December 31, 2025.
- Company raised $6.8 million in gross proceeds during Q1 2026 through a $4.6 million warrant inducement and a $2.25 million private placement.
- The company has 45 days (until June 1, 2026) to submit a plan to regain compliance.
- If the plan is accepted, Nasdaq may grant an extension until October 14, 2026.
Vivos Therapeutics, Inc. issued a press release on April 15, 2026, announcing its financial results for the fiscal year ended December 31, 2025. The filing serves as a routine disclosure of the company's annual financial performance.
📋 Key Facts
- The report was filed on April 15, 2026, regarding the fiscal year ended December 31, 2025.
- The company furnished a press release as Exhibit 99.1 under Item 2.02.
- The filing was signed by Bradford Amman, Chief Financial Officer.
Vivos Therapeutics entered into a $2.25 million PIPE offering with V-Co Investors 3 LLC, consisting of $850,000 in new cash and the conversion of a $1.4 million bridge note. The transaction is highly dilutive, involving the issuance of common stock, pre-funded warrants, and two series of common stock purchase warrants.
🚩 Red Flags
- Significant dilution: The total warrant coverage (including pre-funded) represents over 3.9 million shares against only 1.35 million common shares sold.
- Bridge note conversion: The conversion of a debt instrument issued only months prior (January 2026) suggests immediate liquidity needs.
- High cost of capital: The converted bridge note carried a $140,000 original issue discount (OID).
- Investor fee reimbursement: The company paid $50,000 for the investor's counsel, which is a high friction cost for an $850,000 cash raise.
📋 Key Facts
- The PIPE offering closed on March 31, 2026, with V-Co Investors 3 LLC, an affiliate of New Seneca Partners Inc.
- The company sold 1,353,625 shares of common stock and a pre-funded warrant for 429,957 shares at a price of $1.34 per unit.
- The offering included Series A and Series B warrants to purchase an aggregate of 3,567,164 shares at an exercise price of $1.09.
- A $1,400,000 bridge promissory note from January 15, 2026, was automatically converted into this PIPE offering.
- The company received only $850,000 in new cash proceeds from the closing.
- Vivos is required to file a resale registration statement within 45 days of closing.
- The company paid $50,000 of the investor's legal fees.